A phase 1/phase 2 study will evaluate the efficacy and safety of azeliragon for patients refractory to first-line treatment for metastatic pancreatic cancer.Azeliragon (Cantex Pharmaceuticals) is an oral once-daily therapy that inhibits interactions of the receptor for advanced glycation end products (RAGE) with certain ligands, including S100 and HMGB1 proteins in the tumor microenvironment.
English (US) ·